MedTrace Logo

High-Load, Low-Load, and Passive Blood Flow Restriction in Competitive Sprinters

NCT07438535 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2026-02-27

No results posted yet for this study

Summary

This randomized clinical trial will include competitive male and female sprinters aged 16-30 years, recruited through purposive sampling. Participants will be randomly assigned to one of three groups: (A) HL-BFR (70-85% 1RM with BFR during sets), (B) LL-BFR (20-30% 1RM with BFR), or (C) Passive BFR (BFR applied between sets). The intervention will consist of a 6-week sprint-specific resistance training program performed thrice weekly, incorporating resisted sprints, barbell step-ups, hip thrusts, Nordic curls, and bounding exercises. Strength will be measured using 1RM testing, explosive power through countermovement and standing broad jumps, and sprint performance via 10m, 30m, and 100m timed sprints. Subjective exertion will be tracked using the sRPE scale.

The study aims to determine whether HL-BFR, LL-BFR, or passive BFR produces superior improvements in sprint performance and neuromuscular strength. It is hypothesized that HL-BFR may yield greater adaptations due to combined mechanical and metabolic stress, though LL-BFR and passive BFR may offer practical, low-impact alternatives.

Conditions

  • Blood Flow Restriction

Interventions

OTHER

High-Load Blood Flow Restriction Training (HL-BFR)

In the High-Load BFR group, participants will perform resistance exercises at 70-85% of one-repetition maximum (1RM) with BFR applied during exercise sets.

OTHER

Low-Load Blood Flow Restriction Training (LL-BFR)

In the Low-Load BFR group, participants will perform resistance exercises at 20-30% of one-repetition maximum (1RM) with BFR applied during exercise sets.

OTHER

Passive Blood Flow Restriction Training (PBFR)

In the Passive BFR group, participants will perform resistance exercises at 70-85% of one-repetition maximum (1RM) with BFR applied only during rest intervals between sets.

Sponsors & Collaborators

  • Riphah International University

    lead OTHER

Principal Investigators

  • Muhammad Mubarak Janjua, MS PT · Riphah International University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-12-01
Primary Completion
2026-08-01
Completion
2026-09-01

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07438535 on ClinicalTrials.gov